Source: iStock/© KatarzynaBialasiewicz
Source: iStock/© KatarzynaBialasiewicz

Asuragen agreed to collaborate with Illumina to set up a framework for the development and commercialization of sequencing-based companion diagnostics in partnership with biotech and pharmaceutical companies. Asuragen officials say they will leverage the Quantidex™ NGS product platform for development of customized companion diagnostics for its biotech and pharma partners on the Illumina MiSeqDx™ instrument

Asuragen’s recently launched Quantidex Pan Cancer [research] Kit demonstrates its optimized NGS system that unifies pre-analytical DNA QC, sample quantification, multiplex PCR enrichment, dual-index barcoding, and library purification and quantification, using reagents provided in a single kit, according to Matt McManus, president and CEO of Asuragen.. “It integrates Asuragen’s analytics and reporting suite, the Quantidex Reporter, providing a straight forward sample-to-answer solution for Asuragen NGS panels,” he added.








This site uses Akismet to reduce spam. Learn how your comment data is processed.